5AM Venture Management LLC purchased a new stake in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 738,972 shares of the company's stock, valued at approximately $10,995,903. Biohaven comprises about 0.0% of 5AM Venture Management LLC's investment portfolio, making the stock its 11th largest position. 5AM Venture Management LLC owned about 0.49% of Biohaven at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Janus Henderson Group PLC lifted its position in Biohaven by 1,145.9% during the 1st quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company's stock worth $148,214,000 after buying an additional 16,127,247 shares in the last quarter. BlackRock Inc. bought a new stake in Biohaven during the 2nd quarter worth about $196,574,000. Suvretta Capital Management LLC grew its holdings in Biohaven by 83.0% during the 4th quarter. Suvretta Capital Management LLC now owns 10,286,937 shares of the company's stock worth $116,140,000 after acquiring an additional 4,666,666 shares during the last quarter. Stifel Financial Corp grew its holdings in Biohaven by 50.3% during the 4th quarter. Stifel Financial Corp now owns 9,939,856 shares of the company's stock worth $112,221,000 after acquiring an additional 3,328,506 shares during the last quarter. Finally, Infinitum Asset Management LLC grew its holdings in Biohaven by 267.6% during the 4th quarter. Infinitum Asset Management LLC now owns 6,250,000 shares of the company's stock worth $70,562,000 after acquiring an additional 4,550,000 shares during the last quarter. 88.78% of the stock is owned by institutional investors.
Biohaven Price Performance
Shares of BHVN stock opened at $15.41 on Friday. Biohaven Ltd. has a 1 year low of $7.48 and a 1 year high of $18.57. The firm's 50 day moving average is $14.82 and its 200-day moving average is $11.88. The firm has a market capitalization of $2.33 billion, a price-to-earnings ratio of -3.32 and a beta of 1.26. The company has a current ratio of 4.73, a quick ratio of 4.73 and a debt-to-equity ratio of 21.23.
Biohaven (NYSE:BHVN - Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.91) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.15). Sell-side analysts forecast that Biohaven Ltd. will post -3.3 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on BHVN shares. Royal Bank Of Canada upped their target price on shares of Biohaven from $22.00 to $23.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of Biohaven in a research report on Friday, June 26th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Biohaven in a research report on Tuesday, June 2nd. Needham & Company LLC set a $11.00 target price on shares of Biohaven in a research report on Monday, June 29th. Finally, Canaccord Genuity Group set a $21.00 target price on shares of Biohaven in a research report on Friday. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $18.94.
Check Out Our Latest Analysis on BHVN
About Biohaven
(
Free Report)
Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.
The company's most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.
Featured Stories
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Biohaven, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biohaven wasn't on the list.
While Biohaven currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
